04/01/2026
Everyone is watching the COMP360 psilocybin study like it’s the answer.
It’s not.
The results matter. People improved. That’s real. But the story forming around it is too narrow. It assumes the compound is the main driver of change, as if mental health is just chemistry and the right input fixes the problem.
That model breaks down fast.
What these studies measure is short-term symptom reduction in controlled environments. What they don’t capture is what actually creates lasting change.
In real life, it’s not one thing.
It’s preparation.
It’s safety.
It’s the nervous system.
It’s being seen.
It’s emotional honesty.
It’s integration.
It’s community.
It’s behavior change.
It’s belief change.
The medicine can open something. It can catalyze. But it doesn’t sustain the shift on its own.
People aren’t struggling in isolation inside their brains. They’re struggling in patterns, relationships, and environments that keep reinforcing the same outcomes.
You don’t take something once and override all of that.
This is the gap between clinical trials and lived transformation.
The research is useful. It’s a step. But it’s not the full picture. And treating it like it is risks repeating the same mistake mental health has made for decades: reducing something complex into something simple because it’s easier to measure.
The compound is not the work 🍄
